During the past decade, there has been a revolution in cancer therapeutics by the
emergence of antibody-based immunotherapies that modulate immune responses against …

Baseline cardiovascular assessment before the initiation of potentially cardiotoxic cancer
therapies is a key component of cardio-oncology, aiming to reduce cardiovascular …

Abstract Background and Aims Previous studies found that frailty was an important risk factor
for cardiovascular disease (CVD). However, previous studies only focused on baseline …

Immune checkpoint inhibitors (ICIs) are approved as the first-line drug for treating many
cancers and has shown significant survival benefits; however, it also causes immune-related …

In recent years, immune checkpoint inhibitors (ICIs) have become a widely used treatment
for non-small cell lung cancer (NSCLC), and the combination with traditional radiotherapy …

The risk for suffering immune checkpoint inhibitors (ICIs)‐associated myocarditis increases
in patients with pre‐existing conditions and the mechanisms remain to be clarified. Spatial …

Immune checkpoint molecules are physiological regulators of the adaptive immune
response. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting …

Simple Summary Metastatic melanoma treatment has greatly changed in the last decade
due to the introduction of target therapies and immune checkpoint inhibitors. The …

The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started
with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy …

Simple Summary This review comprehensively summarizes the pathogenic mechanisms
responsible for immune-related Adverse Events (irAEs) arising from self-tolerance loss due …